ESMO Share this item Dr. Michelino De Laurentiis is speaking on "Ribociclib dose reduction on OS in M3 and M7."
ESMO 2020: Dr. Sara Hurvitz: Ribociclib and resistance to prior ET in the M3 and M7 Dr. Sara Hurvitz is speaking on "Ribociclib and resistance to prior ET in the M3 and M7". ESMO 00:02:49
Is it easy to show overall survival in 1L HR+ HER2 – ABC? Dr. Mattea Reinisch is talking on "Is it easy to show overall survival in 1L HR+ HER2 – ABC?" Kisqali Channel 00:03:14
Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ? Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?" Kisqali Channel 00:03:08
All CDK4/6 have shown superior OS results? Dr. Michelino De Laurentiis is speaking on "ALL CDK4/6 have shown superior OS results?" Kisqali Channel 00:03:34
In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this? Dr. Grazia Arpino is sharing her thoughts "In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor." Kisqali Channel 00:02:23
Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant? Dr. Tanja Fehm is discussing on "Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?" Kisqali Channel 00:02:25
